Martine A. Rothblatt, chairperson and chief executive officer of United Therapeutics Corp (NASDAQ: UTHR), sold 8,160 shares of common stock on November 5, 2026, for a total of about $4.33 million. The sales prices ranged from $562.18 to $591.84 per share, according to the Form 4 filing dated November 6, 2026.
The sales were made under a pre-arranged 10b5-1 trading plan that Rothblatt adopted on November 7, 2025.
Concurrently, Rothblatt exercised options to acquire 9,500 shares at an exercise price of $117.76 per share, about $1.12 million in total. The options vested in equal installments on March 15, 2021, 2022 and 2023, and the exercise was also part of the same plan.
After these transactions, Rothblatt directly holds 40,513 shares. The filing also lists indirect holdings, including 326,403 shares in family trusts where she shares investment power and is a beneficiary, and 8,902 shares in family trusts where she is a trustee or settlor. It further lists 81,410 stock options held indirectly through a family trust.
The source states that the stock traded near $562, up 25% over the past year. InvestingPro analysis, cited in the source, suggests the shares may be overvalued at current levels. That view is the analysis service's, not a finding of this report.